Bladder Cancer

IMV's MVP-S Doublet Combo Therapy Shows Encouraging Anti Tumor Activity

ImmunityBio Expects To Submit US Application For VesAnktiva In Bladder Cancer This Month

ImmunityBio's Ankitva Shows 100% Survival At Two Years In Bladder Cancer Setting

ImmunityBio Expects To Submit US Application For VesAnktiva In Bladder Cancer This Month

ImmunityBio's Ankitva Shows 100% Survival At Two Years In Bladder Cancer Setting

Astellas Pharma - Seagen's Enfortumab Shows 36% Pathologic Complete Response In Bladder Cancer Patients

IMV's Basket Clinical Study Shows Promising Top Line Data In Bladder Cancer

Astellas Pharma - Seagen's Enfortumab Shows 36% Pathologic Complete Response In Bladder Cancer Patients

IMV's Basket Clinical Study Shows Promising Top Line Data In Bladder Cancer

Sesen Bio To Conduct Additional Trial For Potential Resubmission Of Vicineum In Bladder Cancer

Sesen Bio Shares Gain On FDA Type A Meeting On Issues From Vicineum Response Letter

Bladder Cancer Recent News

ImmunityBio Meets Endpoint In Second Indication Cohort In Bladder Cancer Trial

Astellas Pharma's Bladder Cancer Treatment Scores Approval In Japan

Nektar, Merck Germany, Pfizer Join Forces For Mid-Stage Bladder Cancer Study

Janssen Shares Erdafitinib Combo Therapy Data In Bladder Cancer

FDA Extends Full Approval For Merck's Keytruda In 1st-Line Bladder Cancer

After FDA Rejection Troubled Biotech Pulls Europe Application For Bladder Cancer Drug

Two weeks ago, Sesen Bio Inc (NASDAQ: SESN) was on the cusp of winning FDA approval for the cancer drug Vicineum.

Bristol Myers Scores FDA Approval For Opdivo In Postsurgery Bladder Cancer

Sesen Bio's Bladder Cancer Trial Wrecked By Misconduct: Stat News

Sesen Bio Inc (NASDAQ: SESN) said that it was not expecting a CRL from the FDA for its bladder cancer candidate Vicineum.

Sesen Bio Stock Crashes As FDA Shoots Down Its Bladder Cancer Pitch

Fusion Pharma Stock Is Trading Higher As FDA Clears Early-Stage Study For Radiopharmaceutical In Neck, Bladder Cancers

G1 Therapeutics Starts Mid-Stage Bladder Cancer Trial With Cosela

Oncologic Drugs Adcomm Backs Merck's Keytruda, Roche's Tecentriq Accelerated Approvals In Bladder Cancer

Roche Walks Away From Regular FDA Nod For Tecentriq In Pretreated Bladder Cancer

Roche Holding AG (OTCMKT: RHHBF) has joined AstraZeneca Plc (NASDAQ: AZN) in withdrawing cancer immunotherapies from the U.S.

Sesen Bio's Vicineum US Application For Bladder Cancer Accepted For Review; Shares Spike

For Eleven Biotherapeutics, Cancer Trial Outcomes Could Be 'Major Catalyst'